4D Molecular Therapeutics FDMT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's operating cash flow?
- 4D Molecular Therapeutics (FDMT) reported operating cash flow of -$68.13M in Q1 2026.
- How has 4D Molecular Therapeutics's operating cash flow changed year-over-year?
- 4D Molecular Therapeutics's operating cash flow decreased by 42.6% year-over-year, from -$47.76M to -$68.13M.
- What is the long-term trend for 4D Molecular Therapeutics's operating cash flow?
- Over 3 years (2021 to 2024), 4D Molecular Therapeutics's operating cash flow has grown at a 24.9% compound annual growth rate (CAGR), from -$69.13M to -$134.59M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.